OpportunityAnalyzer:頭頸椎扁平表皮癌症 (HNSCC) - 機會分析與預測
OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024
|出版日期||內容資訊||英文 250 Pages
|OpportunityAnalyzer:頭頸椎扁平表皮癌症 (HNSCC) - 機會分析與預測 OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024|
|出版日期: 2016年02月02日||內容資訊: 英文 250 Pages||
主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的頭頸椎扁平表皮癌症 (HNSCC) 的治療藥市場，預計從2014年的3億8,600萬美元，到2024年擴大到15億3,000萬美元，以14.8％的年複合成長率 (CAGR) 成長。
本報告提供頭頸椎扁平表皮癌症 (HNSCC) 的治療藥市場相關調查分析，疾病概要，流行病學，目前治療選項，未滿足需求和機會，研究開發策略，開發平台評估等相關的系統性資訊。
The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists in the HNC market, leaving an area of considerable opportunity for interested new comers. Cisplatin is the standard treatment for HNC, due to its greater efficacy over other chemotherapy agents. However, as a cytotoxic agent, its use is limited by its high toxicity and poor safety profile.
The recent investment in HNC has seen a significant increase in research activity. The launch of new agents into the market and continued innovation in the developmental pipeline promises to produce a dynamic market over the forecast period.
The report will enable you to -